SH2D1B and neuroblastoma: To address if the SLAMF7 pathway in macrophages could be activated and contribute to the anti-high-risk neuroblastoma immune response, we investigated the prognostic effect of SLAMF7 and SH2D1B. We found that high expression of both SLAMF7 and SH2D1B expression was significantly associated with better outcome of the patients in Cohort 1 (Fig. 7A) and Cohort 2 (Fig. 7B).